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though airway mucus dehydration is key to pathophysiology of cystic
fibrosis (CF) and other airways diseases, measuring mucus hydration
is challenging. We explored a robust method to estimate mucus
hydration using sialic acid as a marker for mucin content. Terminal
sialic acid residues from mucins were cleaved by acid hydrolysis from
airway samples, and concentrations of sialic acid, urea, and other
biomarkers were analyzed by mass spectrometry. In mucins purified
from human airway epithelial (HAE), sialic acid concentrations after
acid hydrolysis correlated with mucin concentrations (r2  0.92).
Sialic acid-to-urea ratios measured from filters applied to the apical
surface of cultured HAE correlated to percent solids and were ele-
vated in samples from CF HAEs relative to controls (2.2  1.1 vs.
0.93  1.8, P  0.01). Sialic acid-to-urea ratios were elevated in
bronchoalveolar lavage fluid (BALF) from -epithelial sodium chan-
nel (ENaC) transgenic mice, known to have reduced mucus hydration,
and mice sensitized to house dust mite allergen. In a translational
application, elevated sialic acid-to-urea ratios were measured in
BALF from young children with CF who had airway infection relative
to those who did not (5.5  3.7 vs. 1.9  1.4, P  0.02) and could be
assessed simultaneously with established biomarkers of inflammation.
The sialic acid-to-urea ratio performed similarly to percent solids, the
gold standard measure of mucus hydration. The method proved robust
and has potential to serve as flexible techniques to assess mucin
hydration, particularly in samples like BALF in which established
methods such as percent solids cannot be utilized.
mucins; mass spectrometry; dehydration
HEALTHY AIRWAYS finely regulate absorption vs. secretion on
airway surfaces to maintain appropriate hydration of the mucus
layer, which is critical to effective mucociliary transport (2).
These regulatory processes are often disrupted as part of
disease pathogenesis, leading to increased mucus concentra-
tions. Cystic fibrosis is perhaps the best known example of this
disruption, with loss of the CFTR chloride channel leading to
airway surface liquid (ASL) volume depletion and airway
mucus dehydration (7). More recently, elevated airway mucus
concentrations have also been reported in other diseases in-
cluding asthma (24) and chronic obstructive pulmonary disease
(COPD) (1).
Although measuring mucus concentration is critical to un-
derstanding airways disease pathophysiology, assessing airway
hydration status in vivo poses considerable challenges. Mucins
themselves can be difficult to measure since they are extremely
large macromolecules whose heavy glycosylation shields most
of the protein backbone from immunological measurement
techniques (18). The more exposed NH2- and COOH-terminal
regions can be recognized by antibodies but are prone to
proteolytic degradation in the setting of disease that can make
immunological detection unreliable (19). Physical methods
such as refractometry can be used to assess macromolecular
content (18, 22) but require specialized equipment and exper-
tise.
Given the challenges of measuring mucins directly, the
practical gold standard for assessing the concentration of air-
way mucus is to measure its % solid content (4, 18). Percent
solids is defined as the dry weight of the solid content, typically
dominated by mucins, divided by the total wet weight of the
ASL sample. This method has been shown to closely track the
intact mucin concentration in sputum as assessed by physical
techniques (1). While conceptually simple, accurately assess-
ing dry and wet weights requires collection of neat airway
samples without perturbing the hydration state, typically as
expectorated sputum. However, this makes % solids difficult to
utilize when airway samples volumes are small and/or are
diluted during recovery, e.g., with bronchoalveolar lavage
(BAL), which is particularly relevant to animal models and
children.
As an alternative approach, we hypothesized that small
molecule biomarkers that correlate with the solid (mucin) and
the fluid phases of ASL could be used to develop a surrogate
measure of mucus concentration. Mucins contain a large num-
ber of terminal sialic acid residues that can be released through
acid hydrolysis (5, 8), and sialic acid concentrations measured
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after hydrolysis could in theory serve as a marker of the solid,
mucin phase of ASL. The fluid phase could be assessed
through analysis of urea, which is found in a relatively narrow
range in most mammals and diffuses freely throughout fluid
compartments (9). Therefore, we hypothesized that the sialic
acid-to-urea ratio (SA/Urea) could function as a marker of
mucus concentration similar to percent solid measures. An
advantage of the SA/Urea ratio is that it could be applied to
sample types such as BALF in which dilution of airway
secretions during lavage makes percent solid measurements
impossible. Furthermore, since both sialic acid and urea can be
measured via mass spectrometry (11, 32), we hypothesized that
using sensitive mass spectroscopic methods would permit
application in small volume samples as well as simultaneous
measurement of other metabolomic biomarkers.
To test these hypotheses, we developed mass spectrometric
methods to measure sialic acid and urea, then applied these
methods to model systems known to exhibit altered mucus
concentrations including cystic fibrosis (CF) human airway
epithelia and mouse models of disease (26). We then deter-
mined whether these methods could be used to address factors
in early CF lung disease associated with changes in mucin
hydration.
METHODS
Human airway epithelia (HAE) were grown at air-liquid interface,
and mucus was obtained from the apical surface as previously de-
scribed (16, 21). Briefly, excess surgical tissue was procured by the
University of North Carolina (UNC) Tissue Core Facility. Normal
human bronchial epithelial cells were cultured on 0.4-mm pore-sized
Millicell membranes (Millipore, Billerica, MA) coated with collagen
and maintained in air-liquid interface medium (UNC Tissue Core) as
described in Ref. 20. Over a period of 6 wk, confluent cultures
developed cilia and transported mucus. Apical mucus samples were
obtained by gently placing preweighed nitrocellulose filters on the
apical surface of the HAE and allowing them to equilibrate over 12 h.
Urea was added to the basolateral medium at a concentration of 10
M at least 24 h before the filters. Filters were removed, weighed, and
dried to completeness in a 100°C oven and reweighed to obtain
percent solids measures defined as (dry weight of filter  filter
weight)/(wet weight of filter  filter weight).
BAL fluid (BALF) samples from mice were collected as previously
described (23) from mice overexpressing the Scnn1b gene, which
codes for the -subunit of ENaC, a sodium channel expressed, in
airway epithelial cells (ENaC-Tg mice) (27). These mice were
backcrossed to the C57BL/6N background, and the colony was
maintained by breeding transgenic to wild-type (WT) mice. Offspring
were genotyped, and WT littermates served as controls. BALF was
obtained by lavage with PBS at 7.5 mo of age. BALF was also
collected via these methods from 2- to 3-mo-old C57/B6J mice
sensitized to house dust mite antigen (HDM) (Greer, Lenoir, NC) as
previously described (33). Briefly, mice were sensitized by intranasal
inhalation of 1 g HDM daily  2 days, then exposed to 10 g HDM
by intranasal inhalation daily  7 days. BALF was collected 12–24 h
after the last HDM exposure. All animals were housed in individually
ventilated microisolator cages in a facility maintained at the UNC at
Chapel Hill on a 12-h day/night cycle. They were fed a regular chow
diet and given water ad libitum. All animal procedures were approved
by the Institutional Animal Care and Use Committee of the UNC at
Chapel Hill and performed according to the principles outlined by the
Animal Welfare and the National Institutes of Health (NIH) guide-
lines for the care and use of animals in biomedical research.
BALF samples from human subjects were collected as part of a
previous studies (10, 14) using 1–2 aliquots of 1 ml/kg of sterile saline
as the lavage fluid. The sample set included samples collected at the
UNC (n  10) and Australian Respiratory Early Surveillance Team
for CF (AREST CF) (n  4). All studies were approved by the UNC
IRB (IRB nos. 07-0787, 12-1538).
Acid hydrolysis to release sialic acid was performed by adding
formic acid to a final concentration of 1% and incubating the samples
at 80° for 1 h. Before incubation, an internal standard solution of
isotopically labeled purines, urea, and amino acids was added to the
samples as previously described (12, 13). The internal standard was
modified to include [13C]sialic acid at a final concentration of 100
M. Samples from HAE were centrifuged at 11,000 g for 5 min, and the
supernatant was utilized for mass spectrometry as described below.
BALF samples were centrifuged through a 10-kDa size-selection filter
(EMD Millipore, Billerica, MA) before mass spectrometry.
Mass spectrometry was performed via a previously described
method (10) using a Quantum-Ultra triple quadrupole mass spectrom-
eter (Thermo-Finnigan, San Jose, CA) in multiple reaction monitoring
mode with chromatographic conditions similar to those previously
described [UPLC T3 HSS C18 column, methanol/formic acid gradi-
ents (11, 12)]. The previous method was modified to include moni-
toring transitions specific for sialic acid (m/z 308¡87 in negative
mode) and [13C]sialic acid (m/z 311¡90 in negative mode). All
samples were filtered through a 10-kDa size selection filter (EMD
Millipore) before analysis. Biomarker signals were defined as ratios to
the relevant internal standard using the stable isotope dilution method
(6) to control for losses during processing and matrix effects on mass
spectrometric detection. Concentrations were calculated via compar-
isons to standard solutions run in parallel.
RESULTS
To determine whether sialic acid could serve as a surrogate
marker for mucins, we made serial dilutions of ASL isolated
from cultured HAE cells in which the mucin content had been
determined (21). Previously described methods for acid hydro-
lysis of terminal mucin sialic acid residues (8, 29) were
modified to use formic acid, which is more compatible with our
mass spectrometric analysis technique. After treatment with
1% formic acid at 80°C for 1 h, we observed a strong corre-
Fig. 1. Relationship between mucin concentration and acid hydrolyzed sialic
acid concentrations. Human airway secretions were isolated from human
airway epithelial (HAE) allowed to accumulate mucins to high concentration,
measured for percent solid content, then serially diluted over the range 0.45 to
9% solids. Each dilution was treated with formic acid and heat as described,
and the sialic acid concentrations were measured by mass spectrometry (n 
3 per dilution). Sialic acid concentrations were highly correlated to percent
solids. There was a significant linear relationship between percent solids and
sialic acid (r2  0.92, P  0.001), although the curve of best fit was a
second-order polynomial (r2  0.98).
lation between sialic acid and percent solid measurements in
these human airway samples (Fig. 1). The correlation was
generally linear (r2  0.92), though due to modest deviations
at high percent solids the curve of best fit was a second-order
polynomial.
We next assessed whether this approach could be utilized to
directly measure mucus concentrations in a cell culture model
of HAE grown at air-liquid interface. As a marker of the fluid
phase of ASL, we chose to measure urea, since it freely
diffuses through fluid compartments and is commonly utilized
as a marker of airway fluid dilution (28). However, since we
observed that HAE do not typically produce significant con-
centrations of urea (data not shown), we added urea to the
basolateral medium to simulate in vivo conditions. Urea was
allowed to equilibrate throughout the fluid phase for at least 24
h before experiments.
Filters were placed on the apical surface of HAE, allowed to
absorb mucus, then removed and assessed for percent solids
(wet-to-dry ratios). The dried filters were then acid hydrolyzed
to release mucin sialic acid and analyzed by mass spectrome-
try. To ensure that the acid hydrolysis did not alter urea
concentrations, we obtained aliquots from three filters before
treatment as well as 1 h and 2 h after incubation with 1%
formic acid at 80°C. In these experiments, sialic acid concen-
trations increased 	40-fold after 1 h of treatment (Fig. 2A), but
urea concentrations were not changed. Extending the 80°C
incubation time to 2 h did not significantly increase sialic acid
or alter urea concentrations.
We then measured SA-to-urea ratios (SA/Urea) in a larger
number of filters and compared results with percent solid
measures obtained by standard wet-to-dry methods. We ob-
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Fig. 2. Sialic acid (SA)-to-urea ratios (SA/Urea)
in human airway epithelia. A: treatment of filters
(n  3) applied to the apical surface of HAE with
1% formic acid at 80° for 1 or 2 h resulted in a
significant increase in SA concentrations (solid
diamonds) but did not impact urea concentrations
(shaded circles). B: SA/Urea was correlated with
% solids (r  0.61, P  0.01) except at very high
% solid concentrations (	5%). C: SA/Urea was
correlated with % solids in HAE allowed to
accumulate mucus to higher % solid concentra-
tions. D: airway surface liquid (ASL) height was
not correlated with SA/Urea (r  0.1, P 	 0.5) or
to % solids (r  0.1, P 	 0.5, not shown),
reflecting the fact that the thickness of the mucin
layer is not necessarily proportional to its concen-
tration. E: SA/Urea ratio was elevated in filters
obtained from HAE from patients with cystic
fibrosis (CF) relative to non-CF controls (Cont).
*P  0.05. Results were comparable to % solids
measures.
percent solids (r  0.61, P  0.01, Fig. 2B). In a small subset
of samples with high percent solids (	5%), SA/Urea were
lower than predicted, and excluding these high outliers
strengthened the correlation considerably (r  0.90, P 
0.001). To determine whether the presence of outliers reflected
a limitation of the method at high percent solid values, we
repeated this experiment with HAE allowed to accumulate
mucus over a longer period of time. SA/Urea remained
strongly correlated with percent solids even at the higher
values (r  0.80, P  0.01, Fig. 2C). Notably, neither SA/Urea
nor percent solids were correlated with total ASL height (Fig.
2D and not shown), as ASL height does not adequately capture
mucin concentration when cultures with variable mucin secre-
tion rates are studied over prolonged intervals with the mucus
layer present.
We next explored whether this method could detect disease
related changes in mucus concentrations by measuring SA/
Urea from filters applied to cultured HAE from patients with
CF compared with those obtained from non-CF patients as
controls. Consistent with the known airway dehydration phe-
notype of cultured CF HAE, SA/Urea in filters from CF cells
were elevated relative to those from controls. The differences
in SA/Urea were comparable to percent solid measures ob-
tained in parallel (Fig. 2E).
To assess whether the SA/Urea approach could detect
mucus concentrations in vivo, we assessed respiratory sam-
ples obtained from ENaC-Tg mice that overexpress the 
subunit of the ENaC sodium channel and have airway
surface dehydration and increased airway mucus concentra-
tions (27). In BALF from these animals, we observed
significantly higher sialic acid concentrations after acid
hydrolysis (Fig. 3A) without significant changes in BALF
urea (Fig. 3B) in ENaC-Tg mice relative to WT controls.
As a result, the SA/Urea ratio was elevated in the
ENaC-Tg mice, consistent with previously published mea-
sures of airway mucus hydration in this model (26).
We also explored the utility of the SA/Urea in an allergic
model of mice sensitized and exposed to HDM. Similar to the
ENaC-Tg mice, HDM-treated mice had higher levels of sialic
acid than control animals (Fig. 3D), consistent with the known
increase in airway mucin production after HDM exposure (30).
BALF urea concentrations were similar in HDM-treated and
control groups (Fig. 3E), resulting in an increased SA/Urea
(Fig. 3F). These data suggest that mucus concentration were
increased in HDM-treated mice, similar to findings previously
reported in asthma (15, 25).
Having demonstrated the utility of the SA/Urea method
within in vitro and in vivo model systems, we next determined
whether this method could provide insight into mucus concen-
trations in human disease. CF airways disease is associated
with accumulation of excessively concentrated mucus, but the
factors that influence the onset and progression of changes in
mucus hydration in early disease are not well established. We
applied the SA/Urea method on BALF from young (6-yr-old)
children with CF available from a previous study (14) grouped
by the presence or absence of pathogens on BALF culture
(Table 1). In these samples, both sialic acid (Fig. 4A) and urea
(Fig. 4B) concentrations were elevated in samples with respi-
ratory infection (	50,000 pathogens/ml). Furthermore, the
SA/Urea was also elevated in culture-positive samples, sug-
gesting that infection is associated with mucus dehydration
(Fig. 4C). Using our mass spectrometric method, we were able
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Fig. 3. Sialic acid, urea, and SA/Urea ratios
in mouse models of airways disease. A–C:
sialic acid and urea were measured in BALF
obtained from mice overexpressing the
-subunit of the epithelial sodium channel
(ENaC) sodium channel (ENaC) as well as
wild-type (WT) controls. Sialic acid con-
centrations were elevated in the ENaC-
overexpressing mouse relative to WT (A),
though urea concentrations were not signif-
icantly different (B). C: SA/Urea ratios
were elevated in the ENaC-overexpressing
mouse, consistent with its known airway
dehydration phenotype. D–F: similar find-
ings were observed in BALF obtained from
mice sensitized then exposed to house dust
mite (HDM) allergen, with increased sialic
acid (D), no change in urea (E), and in-
creased SA/Urea ratios (F) relative to con-
trols. *P  0.05.
to simultaneously measure other established biomarkers and
observe patterns consistent with previous observations (10,
34): elevated AMP, hypoxanthine, and phenylalanine in sam-
ples from patients with infection (Fig. 4D).
DISCUSSION
In this study, we demonstrate the utility of a relatively
simple method to estimate mucin concentrations within respi-
ratory samples using the ratio of acid to hydrolyzed sialic acid
as a marker of secreted mucins and urea as a marker of the fluid
phase of ASL. The SA/Urea ratio performs similarly to percent
solid measures in cell culture models and is elevated as
predicted in an animal model of airway dehydration. Using this
method, we observed evidence suggesting that infection in
early CF lung disease exacerbates mucus dehydration, likely
by triggering increased mucin, but not liquid secretion. While
this is consistent with known CF pathophysiology, it has been
difficult to measure in early disease using previous methods.
The SA/Urea offers a straightforward method to estimate
mucus hydration when other methods are not feasible or
practical. Although we chose to utilize mass spectrometry for
detection, more conventional colorimetric assays are commer-
cially available for both sialic acid and urea, which broadens
the potential application of this approach. One advantage of
using mass spectrometry is the ability to measure other inflam-
matory biomarkers simultaneously with mucus concentration,
including compounds such as purines that modulate both in-
flammation and hydration (3). Indeed, we were able to observe
changes in inflammatory biomarkers with infection in young
children with CF that parallel findings in our previous studies
(10, 14, 34).
One potential limitation to this approach is that sialic acid
concentration in airway samples could be altered by changes in
the sialic acid content of individual mucin molecules. Previous
studies have reported that total mucin sialic acid content is
elevated in CF (8, 35), though other studies have suggested that
this difference is primarily related to increase in total mucins
(29). Another disadvantage reflects the limitations of using
urea as a dilution marker in BALF. Urea likely diffuses into
lavage fluid during lavage, limiting its accuracy as a dilution
marker, though no superior marker has been established (17).
Notably, we have observed increased urea concentrations in
BALF from subjects with more significant disease (10), which
may reflect accumulation of secretions in airways with reduced
mucociliary clearance. Despite these limitations, we were able
to observe the biologically plausible differences in SA/Urea in
BALF both mouse models and human subjects, suggesting that
these issues do not obviate the utility of this approach.
In summary, we report a relatively simple measure to assess
mucus hydration that is applicable to a variety of respiratory
Table 1. Demographics of human CF subjects
Infected Not Infected P Value
Age, yr 3.6  1.5 4.1  2.3 0.663
Sex, % male 67% 38% 0.592
% Neutrophils in BALF 72.5%  21.5% 24.5%  20.3% 0.001




Fig. 4. SA/Urea ratios in CF airways disease.
Sialic acid, urea (B), and other biomarkers were
measured in BALF obtained from young (6 yr
old) children with CF. Sialic acid (A), urea (B),
and the SA/Urea ratio (C) were elevated in BALF
from which respiratory pathogens were recovered
on culture compared with culture negative sam-
ples. D: other metabolomic biomarkers measured
simultaneously with sialic acid and urea con-
formed to previously observed patterns in CF,
with elevated concentrations of AMP, hypoxan-
thine (Hyp), and phenylalanine (Phe) in culture
positive (
) vs. culture () samples. Adenosine
(Ado) was nonsignificantly decreased in culture
(
) samples (P  0.26). *P  0.05.
sample types. While this method does not replace more sophis-
ticated mucin measures or gravimetric approaches, it does
permit estimates of mucus concentration when more estab-
lished methods such as % solid measures are not practical.
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